Germany - Drugs

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure designation "open procedure" (Section IV.1.1) used in the text of this announcement is due to the requirements of the announcement form. Neither this nor the use of the "TED" medium is associated with any submission to procurement law regulations, the application of which is not mandatory by virtue of the law or procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The subject of the agreement are drugs containing the active ingredient atovaquone. The contract covers drugs containing the active ingredient combination bimatoprost + timolol in an ophthalmic, non-divided dosage form. The subject of the agreement are medicinal products containing the active substance combination bimatoprost + timolol in an ophthalmic, divided dosage form. The subject of the contract are medicinal products containing the active ingredient budesonide with the ATC code A07EA06. The subject of the contract are medicinal products containing the active ingredient capsaicin in the administration form of patches (prescription-only preparations). The subject of the contract are medicinal products containing the active ingredient chlortalidone. The subject of the Agreement are drugs containing the active ingredient dornase alfa. The Contractual Products are medicinal products containing the active substance everolimus with the ATC code L04AA18. The subject of the agreement are medicinal products containing the active ingredient lidocaine in the form of a patch. The subject of the contract are medicinal products containing the active ingredient loratadine. The subject of the Agreement are medicinal products containing the active ingredient mercaptopurine. The Contractual Products are medicinal products containing the active ingredient mesalazine in an oral dosage form. The subject of the Agreement are medicinal products containing the active ingredient mesalazine in a rectal foam dosage form. The subject of the Agreement are medicinal products containing the active ingredient mesalazine in the form of suppositories. The subject of the Agreement are medicinal products containing the active ingredient olanzapine. The subject of the agreement are medicinal products containing the active ingredient permethrin. The subject of the Agreement are medicinal products containing the active ingredient pipamperone. The Contractual Products are medicinal products containing the active ingredient pyridostigminium cation in the dosage forms tablet and coated tablet. The subject of the Agreement are medicinal products containing the active ingredient ranolazine. The subject of the Agreement are medicinal products containing the active ingredient tacrolimus in the dosage forms sustained-release tablet or granules for the preparation of an oral suspension. The contract covers medicinal products containing the active ingredient combination telmisartan + amlodipine. The subject of the Agreement are medicinal products containing the active ingredient tranexamic acid in the dosage form film-coated tablet. The contract covers medicinal products containing the active ingredient triamcinolone acetonide in the form of a cream. The contract covers drugs containing the active ingredient combination trifluridine + tipiracil.

Opportunity closing date

01 March 2025

Value of contract

£0-100k